In combined targeted therapy, sorafenib, a first-line targeted drug for advanced hepatocellular carcinoma, was reported to show a great anti-tumor effect when combined with HSP70 inhibitor triptolide [171]. This evidence concerns the gene HSPA1A and hepatocellular carcinoma.